DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Google Secures Pentagon AI Deal for Classified Projects 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
New York, Feb. 22, 2016 -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today announced that company CEO, Michael Nelson, will present at the New York Venture Capital Association 2016 Health & Bio Technology Summit on Tuesday, February 23rd at 4pm at the Microsoft Technology Center in New York, NY.
Intrommune’s lead product, INT-301, is being developed for the treatment of peanut allergies. Peanut allergy is a potentially deadly disease which affects 1.5 million children at an estimated cost of $6.25 billion per year to families in the United States. There is currently no treatment for this condition.
In addition to INT-301 for peanut allergy, Intrommune is also developing the OMIT platform to treat other common food allergies. The 8 most common allergies account for 90% of food allergies in the US. 15 million Americans, including 6 million children, have one or more food allergies.
About Oral Mucosal Immunotherapy
Food allergies affect an estimated 15 million Americans, including 6 million children, and over 220 million people worldwide. Allergen-specific immunotherapy is the only treatment modality that targets the root cause of the disease, consistently exposing the allergy sufferer’s immune system to small amounts of allergen proteins to desensitize them to the allergens over time. There is currently no commercially-available allergy immunotherapy product for food allergies. Oral mucosal immunotherapy (OMIT) uses a specially formulated toothpaste to stabilize and deliver allergenic extracts to the areas of the oral cavity with the greatest potential for allergy desensitization. OMIT promises advantages over existing approaches to allergy immunotherapy due to its targeted delivery, simplified administration, and ease of long-term patient adherence.
About Intrommune Therapeutics
Intrommune is developing the revolutionary oral mucosal immunotherapy (OMIT) treatment platform for food allergies. Intrommune’s lead product, INT-301, is expected to be a safe, effective and convenient therapy for patients who suffer from peanut allergy. OMIT is designed to deliver proteins, such as immunotherapeutic agents, to the immune system while the user brushes their teeth. OMIT is a long-term, patient-friendly, disease-modifying solution for the 220 million people, including 9 million adults and 6 million children in the U.S., who suffer from this life-altering condition.
Danya Glabau Director of Medical Affairs Intrommune Therapeutics [email protected]
